Holen Sie sich die Stockscreener-App
8.3785
0.85%
-0.0715
Handel nachbörslich:
8.36
-0.0185
-0.22%
Schlusskurs vom Vortag:
$8.45
Offen:
$8.494
24-Stunden-Volumen:
15,100
Relative Volume:
0.28
Marktkapitalisierung:
$590.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-7.21%
1M Leistung:
-22.13%
6M Leistung:
-46.21%
1J Leistung:
+0.00%
1-Tages-Spanne:
$8.17
$8.494
1-Wochen-Bereich:
$8.17
$9.459
52-Wochen-Spanne:
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
8.3785 | 595.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Yd Bio Ltd Aktie (YDES) Neueste Nachrichten
YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech - TipRanks
YD Bio (Nasdaq: YDES) builds Taiwan-U.S. FDA regulatory platform - Stock Titan
YD Bio partners with YC Biotech to establish Taiwan-US dual-core regulatory platform - BioSpectrum Asia
YD Bio Says US Unit Selected as FDA Liaison for YC Biotech's Asia Clients - marketscreener.com
Yd Bio Limited announces strategic partnership with Yc Biotech Co - marketscreener.com
SunPower to Participate in the 38th Annual ROTH Conference - The Manila Times
Rumble App Now Includes Rumble Shorts on iPhones Following Apple Approval - The Manila Times
The Chefs’ Warehouse, Inc. to Participate in the UBS Global Consumer & Retail Conference - The Manila Times
Freshworks to Participate in Upcoming Investor Conferences - The Manila Times
The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March - The Manila Times
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Major Shareholder Announcement - The Manila Times
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform - marketscreener.com
Inside YD Bio’s new Taiwan‑U.S. gateway for FDA drug and device approvals - Stock Titan
Ethan Shen holds 77.06% of YD Bio Ltd (YDES) as amended ownership filing - Stock Titan
YD Bio Ltd (YDES) PE Ratio (TTM) Chart - GuruFocus
YD Bio Shares Spark Retail Trader Buzz Following Nasdaq Debut via Breeze SPAC - MSN
CMB.TECH to Release Q4 2025 Earnings on February 26, 2026 - Intellectia AI
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
YD Bio enters into binding LOI to acquire shares, assets of SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million - Investing.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - The Manila Times
Cancer detection firm YD Bio targets $26.87M glioblastoma cell therapy deal - stocktitan.net
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Bio Limited (YDES) board reshaped by majority holders’ written consent - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
YD Bio LtdPlans to evaluate up to three acquisitions in 2026 - marketscreener.com
Yd Bio LtdPlans To Evaluate Up To Three Acquisitions In 2026 - TradingView — Track All Markets
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Yahoo Finance
Micron and Lam Research among market cap stock movers on Tuesday By Investing.com - Investing.com India
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio (YDES) Stock Price, News & Analysis - MarketBeat
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
Finanzdaten der Yd Bio Ltd-Aktie (YDES)
Es liegen keine Finanzdaten für Yd Bio Ltd (YDES) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):